醫(yī)療特長(zhǎng)：
主治原發(fā)性肝癌,、膽囊癌,、膽管癌、胰腺癌,、肝血管瘤,、門脈高壓、上消化道出血,、肝內(nèi)外膽管結(jié)石等良惡性疾病,。擅長(zhǎng)膽囊癌根治術(shù)；肝門部膽管癌根治術(shù)；復(fù)雜膽道結(jié)石手術(shù),；胰頭,、體尾癌根治術(shù)；微創(chuàng)肝切除,、膽囊切除,肝癌射頻消融術(shù)等,。對(duì)原發(fā)性肝癌侵襲轉(zhuǎn)移治療有豐富經(jīng)驗(yàn)。
研究方向：
肝膽胰脾臨床和基礎(chǔ)研究,。
主要教育和工作經(jīng)歷：
學(xué)習(xí)經(jīng)歷：
2001年9月-2004年6月: 中山大學(xué)外科學(xué)專業(yè)就讀,，獲得博士學(xué)位。
工作經(jīng)歷：
2004年7月-至今：中山大學(xué)附屬第一醫(yī)院肝膽外科主治醫(yī)師,、副主任醫(yī)師,、主任醫(yī)師
社會(huì)兼職：
中國(guó)醫(yī)藥教育協(xié)會(huì)醫(yī)療裝備工作委員會(huì)副主任委員；廣東省健康管理學(xué)會(huì)肝膽胰微創(chuàng)專委會(huì)主任委員,；廣東省醫(yī)學(xué)會(huì)肝膽胰外科學(xué)分會(huì)術(shù)中輔助診斷學(xué)組組長(zhǎng),；廣東省醫(yī)師協(xié)會(huì)肝癌學(xué)組副組長(zhǎng)。
論著：
1,、Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis andpromotes tumor progression by regulating P21/CDK2 in hepatocellular Carcinoma《AGING》2020
2,、Bioinformatics analysis on multiple Gene Expression Omnibus datasets ofthe hepatitis B virus infection and its response to the interferon-alphatherapy《BMC Infectious Diseases》2020
3、Uridine-cytidine kinase 2 upregulation predicts poor prognosis ofhepatocellular carcinoma and is associated with cancer aggressiveness.《Molecular Carcinogenesis》 2019
4,、Apatinib potentiates irradiation effect via suppressing PI3K/AKTsignaling pathway in hepatocellular carcinoma.《Journalof Experimental & Clinical Cancer Research》2019
5,、Comprehensive and combined omics analysis revealsfactors of ischemia-reperfusion injury in liver transplantation. 《Epigenomics》 2019
6、Targeting TF-AKT/EGFR Pathway Suppressed theGrowth Of Hepatocellular Carcinoma. 《Frontiers in Oncology》 2019
7,、A comprehensive bioinformatics analysis onmultiple Gene Expression Omnibus datasets of nonalcoholic fatty liver diseaseand nonalcoholic steatohepatitis. 《Sci Rep》 2018
8、Overexpression of signal sequence receptor γ(SSR3) predicts poor survival in patients with hepatocellular carcinoma.《Hum Pathol》 2018
9,、Formylpeptide receptor 1 mediates thetumorigenicity of human hepatocellular carcinoma cells.《OncoImmunology》 2016
10,、High expression of hexokinase domain containing 1is associated with poor prognosis and aggressive phenotype in hepatocarcinoma.《Biochemical and Biophysical ResearchCommunications》 2016
11、Adult hepatic cavernous hemangioma with highlyelevated α?fetoprotein: A case report and review of the literature.《Oncol Lett》 2015
12,、Arterial infusion of 5-fluorouracil combined withsubcutaneous injection of pegylated interferon alpha-2b in treatingunresectable hepatocellular carcinoma with portal vein tumor thrombus.《Med Oncol》 2015
13,、Inhibition of Wnt signaling induces cellapoptosis and suppresses cell proliferation in cholangiocarcinoma cells.《Oncol Rep》 2013
14、The roles of Notch1 expression in the migrationof intrahepatic cholangiocarcinoma.《BMC Cancer》 2013
15,、Development of IGF Signaling Antibody Arrays forthe Identification of Hepatocellular Carcinoma Biomarkers.《 PLos One》 2012
16,、Identification of Max binding protein as a novelbinding protein of Nck1 and characterization of its role in inhibiting humanliver cancer SK-HEP-1 cells. 《Chinese Medical Journal》 2012
17、Experimental study of single-pin punctureasymmetrical hydroablation using a conformational radiofrequency ablationelectrode in ex vivo ox liver.《The British Journal of Radiology》 2012
18,、Killing effects of different physical factors onextracorporeal HepG2 cells of human Hepatoma cell line.《Asian Pacific Journal of Cancer Prevention》 2012
19,、Microwave Ablation Treatment of Liver Cancer witha 2,450-MHz Cooled-shaft Antenna: Pilot Study on Safety and Efficacy.《Asian Pacific Journal of Cancer Prevention》 2012
20、MNT inhibits the migration of humanhepatocellular carcinoma SMMC7721 cells.《Biochemical and Biophysical ResearchCommunications》 2012
21,、Prognostic Analysis for Treatment Modalities inHepatocellular Carcinomas with Portal Vein Tumor Thrombi.《 Asian Pacific Journal of Cancer Prevention》2011
專著：
《肝膽胰脾外科并發(fā)癥學(xué)》
其他主要工作成績(jī)（比如獲獎(jiǎng)情況）：
廣東省高等學(xué)?！扒О偈こ獭钡谖迮瞬排囵B(yǎng)對(duì)象，廣東省健康管理協(xié)會(huì)先進(jìn)個(gè)人，曾在美國(guó)ST-Vicent Hospital 肝膽胰中心進(jìn)行臨床培訓(xùn),。主持省市基金12項(xiàng),。在國(guó)內(nèi)外核心期刊發(fā)表論文60余篇，以第一作者或通訊作者發(fā)表SCI論文30余篇,。廣東省醫(yī)學(xué)科技成果二等獎(jiǎng),。
